Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity - PubMed (original) (raw)

Review

Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity

Carlos J Pirola et al. World J Gastroenterol. 2018.

Abstract

This review intends to uncover how information from large-scale genetic profiling (whole genome sequencing, and whole exome sequencing) of nonalcoholic fatty liver disease (NAFLD), as well as information from circulating transcriptomics (cell-free miRNAs) and metabolomics, contributes to the understanding of NAFLD pathogenesis. A further aim is to address the question of whether OMICs information is ready to be implemented in the clinics. The available evidence suggests that any new knowledge pertaining to molecular signatures associated with NAFLD and nonalcoholic steatohepatitis should be promptly translated into the clinical setting. Nevertheless, rigorous steps that must include validation and replication are mandatory before utilizing OMICs biomarkers in diagnostics to identify patients at risk of advanced disease, including liver cancer.

Keywords: Fibrosis; Genetics; Liver biopsy; Metabolomics; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; PNPLA3; Proteomics; TM6SF2; Transcriptomics; miR122.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: No potential conflicts of interest.

Figures

Figure 1

Figure 1

Brief description of OMICs signatures, including their main applications as biomarkers in clinical practice.

Figure 2

Figure 2

Summary of OMICs biomarkers in the prediction of nonalcoholic fatty liver disease severity.

Figure 3

Figure 3

Whole interactome of compounds (hexagons), chemical reactions (diamonds), enzymes (squares) and genes (circles) associated with nonalcoholic fatty liver disease. Details on the set of genes and metabolites that were included in the analysis can be found in the main text; terms were filtered according to the ones already found in the databases. The interactome was built using Metscape[73], a plug-in for the widely used network analysis software Cytoscape[74] that supports calculation, analysis and visualization of gene-to-metabolite networks in the context of metabolism.

Figure 4

Figure 4

The urea-cycle, glutamate, and branched-chain amino acids in the biology of nonalcoholic fatty liver disease. Sub-network analysis showing the urea-cycle and metabolism of amino acids (L-arginine, L-proline, L-glutamate, L-aspartate and L-asparagine) that were extracted from the interactome shown in Figure 3. Compounds (common names in the Human Metabolome Database,

http://www.hmdb.ca

), chemical reactions, enzymes (KEGG database) and genes (HUGO symbols) are represented by hexagons, diamonds, squares and circles, respectively.

Figure 5

Figure 5

What to expect for the near future. A personalized nonalcoholic fatty liver disease approach by integrating OMICs big data with clinical information.

References

    1. Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-Tetri BA, Rinella ME. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015;1:15080. - PubMed
    1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357. - PubMed
    1. Brunt EM. Histopathology of non-alcoholic fatty liver disease. Clin Liver Dis. 2009;13:533–544. - PubMed
    1. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:195–203. - PubMed
    1. Sookoian S, Pirola CJ. Nonalcoholic fatty liver disease and metabolic syndrome: Shared genetic basis of pathogenesis. Hepatology. 2016;64:1417–1420. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources